Shorter drug course may be safer for kidney transplant patients
NCT ID NCT06374095
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times
Summary
This study looks at two different ways to give anti-rejection drugs to kidney transplant patients. One group gets a single dose of a drug called RATG, while the other gets seven doses over a week. The goal is to see which approach causes fewer side effects like low blood cell counts, while still protecting the new kidney. The study involves 75 adults who received a kidney transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY REPLACEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, 24127, Italy
Conditions
Explore the condition pages connected to this study.